Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | WDR5 | P61964 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470787 | 0.90 | DRD2 (0.58) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL9808215 | 0.87 | LMNA (0.67) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL28540629 | 0.87 | HRH3 (0.57) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL8778541 | 0.87 | HRH3 (0.57) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL535552 | 0.83 | WDR5 (0.55) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL366494 | 0.82 | LMNA (0.57) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL1685432 | 0.82 | DRD2 (0.62) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL9808100 | 0.82 | DRD2 (0.72) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL3957187 | 0.82 | LMNA (0.61) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL2096611 | 0.80 | KMT2A (0.62) | LMNAMAPK1HTTSMN1; SMN2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | claimed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | claimed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | claimed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| CN-101137628-A | Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | claimed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| EP-3071560-B1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2018-01-10 | — | — | EP | disclosed |
| US-9783523-B2 | N-acylimino heterocyclic compounds | BASF SE (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20160297793-A1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2016-10-13 | — | — | US | disclosed |
| CN-105254552-A | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE INC | 2016-01-20 | — | — | CN | disclosed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| CN-101137628-A | Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | disclosed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | disclosed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | disclosed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | disclosed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-6583135-B2 | Treating central nervous system disorders wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). | PHARMACIA & UPJOHN COMPANY | 2003-06-24 | — | — | US | disclosed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-0741694-B1 | PHENYL ACETIC ACID DERIVATIVES, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND AGENTS CONTAINING THEM | BASF AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | disclosed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-0873305-B1 | AZINOOXIMETHERS, PROCESSES AND INTERMEDIATE PRODUCTS FOR MANUFACTURING SAME, AND THE USES THEREOF IN COMBATING HARMFUL FUNGI AND PESTS | BASF AG (DE) | 2001-03-28 | — | — | EP | disclosed |
| US-6187812-B1 | FOR CONTROLLING ANIMAL PESTS OR HARMFUL FUNGI; (E,E,E)-2-METHOXYIMINO-2-(2'-(1?-METHYL, 1?-(1?'-ETHOXYIMINOETHYL))IMINOOXYMETHYL)PHENYLACETIC ACID MONOMETHYLAMIDE, FOR EXAMPLE | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-13 | — | — | US | disclosed |
| US-6127568-A | PESTICIDES, FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-03 | — | — | US | disclosed |
| EP-0873307-B1 | CYANIMINO OXIME ETHERS, PROCESS AND INTERMEDIATES FOR THE PREPARATION AND USE THEREOF FOR THE CONTROL OF NOXIOUS FUNGI AND ANIMAL PESTS | BASF AG (DE) | 2000-05-31 | — | — | EP | disclosed |
| US-6066756-A | FUNGICIDES, PESTICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-23 | — | — | US | disclosed |
| US-6063813-A | FUNGICIDES AND INSECTICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
| US-6043282-A | FUNGICIDES, PESTICIDES, INSECTICIDES, NEMATOCIDES, MITICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-28 | — | — | US | disclosed |
| US-5981581-A | FOR CONTROLLING ANIMAL PESTS OR HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| US-5977399-A | Iminooxymethyleneanilides, preparation thereof and intermediates therefor, and compositions containing them | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-02 | — | — | US | disclosed |
| US-5977146-A | Pyridylcarbamates, process and intermediates for their preparation, and their use | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-02 | — | — | US | disclosed |
| US-5965587-A | PESTICIDES, FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | disclosed |
| EP-0888311-A1 | PYRIMIDYL PHENYL AND BENZYL ETHERS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-07 | — | — | EP | disclosed |
| CN-1192200-A | Phenylacetic acid derivatives, process and intermediates for their preparation, and their use as pest-killing compositions and fungicides | BASF AG (DE) | 1998-09-02 | — | — | CN | disclosed |
| CN-1166829-A | Iminooxymethylene anilides, process and intermediate products for preparing the same and pesticides containing the same | BASF AG (DE) | 1997-12-03 | — | — | CN | disclosed |
| CN-1161687-A | Phenylacetic acid alkyl esters | BASF AG (DE) | 1997-10-08 | — | — | CN | disclosed |
| WO-1997033874-A1 | PYRIMIDYL PHENYL AND BENZYL ETHERS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1997-09-18 | — | — | WO | disclosed |
| CN-1152908-A | Phenyl acetic acid derivatives, process and intermediate products for their production and agents containing them | BASF AG (DE) | 1997-06-25 | — | — | CN | disclosed |
| CN-1143361-A | Phenylacetic acid derivatives, their preparation and intermediates, and compositions containing them | BASF AG (DE) | 1997-02-19 | — | — | CN | disclosed |
| US-4590291-A | Thrombin inhibitory new dihydroxybenzene ether derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-20 | — | — | US | disclosed |
| EP-0068250-A1 | Dioxybenzene ether derivatives, pharmaceutical compositions containing them, process for the preparation thereof and their use | BAYER AG (DE) | 1983-01-05 | — | — | EP | disclosed |
| EP-0068250-A1 | Dioxybenzene ether derivatives, pharmaceutical compositions containing them, process for the preparation thereof and their use | BAYER AG (DE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | LMNA 4162/4885MAPK1 2470/4885HTT 566/4885 |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | LMNA 3236/4885MAPK1 955/4885HTT 3784/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | LMNA 4136/4885MAPK1 2169/4885HTT 430/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | LMNA 3236/4885MAPK1 955/4885HTT 3784/4885 |
| US-20160297793-A1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | CBR3, C5, ALOX5 | LMNA 1636/4885MAPK1 3729/4885HTT 1228/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | LMNA 4162/4885MAPK1 2470/4885HTT 566/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | LMNA 4136/4885MAPK1 2169/4885HTT 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.